These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1428464)

  • 21. [Skin vasoconstriction assay in the evaluation of topical corticosteroids in man. General problems and results obtained in a series of tests (author's transl)].
    Weirich EG; Lutz U
    Dermatologica; 1973; 147(6):353-75. PubMed ID: 4788215
    [No Abstract]   [Full Text] [Related]  

  • 22. Evaluation of the proposed FDA pilot dose-response methodology for topical corticosteroid bioequivalence testing.
    Demana PH; Smith EW; Walker RB; Haigh JM; Kanfer I
    Pharm Res; 1997 Mar; 14(3):303-8. PubMed ID: 9098871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing topical bioavailability and bioequivalence: a comparison of the in vitro permeation test and the vasoconstrictor assay.
    Lehman PA; Franz TJ
    Pharm Res; 2014 Dec; 31(12):3529-37. PubMed ID: 25005736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The influence of vehicule composition and corticosteroids sensitivity on the vasoconstrictor activity of a new topical corticosteroid, difluprednate (author's transl)].
    Girard J; Sagon J; Barbier A; Tardieu JC; Lafille C
    J Pharm Belg; 1978; 33(6):341-50. PubMed ID: 748519
    [No Abstract]   [Full Text] [Related]  

  • 25. Critical factors determining the potency of topical corticosteroids.
    Kirkland R; Pearce DJ; Balkrishnan R; Feldman SR
    J Dermatolog Treat; 2006; 17(3):133-5. PubMed ID: 16854751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generic topical corticosteroids.
    Med Lett Drugs Ther; 1988 May; 30(765):49-50. PubMed ID: 3362092
    [No Abstract]   [Full Text] [Related]  

  • 27. Assessing equivalence of innovator and generic formulations of betamethasone dipropionate cream and ointment.
    Sequira J; Berardi M; Chan TM; Letarte J; Malchow R; Pramanick B; Wolkoff HN
    Clin Ther; 1991; 13(6):687-94. PubMed ID: 1790543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of different desoximetasone preparations compared to other topical corticosteroids in the vasoconstriction assay.
    Borelli C; Gassmueller J; Fluhr JW; Nietsch KH; Schinzel S; Korting HC
    Skin Pharmacol Physiol; 2008; 21(3):181-7. PubMed ID: 18523415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Randomized, Double-Blind, Placebo-Controlled Study of the Vasoconstrictor Potency of Topical 0.25% Desoximetasone Spray: A High to Super High Range of Potency (Class I to Class II) Corticosteroid Formulation.
    Oussedik E; Saleem MD; Feldman SR
    J Drugs Dermatol; 2017 Oct; 16(10):972-975. PubMed ID: 29036250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioequivalence studies of topical preparations: statistical considerations.
    Hauck WW
    Int J Dermatol; 1992 Oct; 31 Suppl 1():29-33. PubMed ID: 1428465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topical corticosteroids: a review of properties and principles in therapeutic use.
    Chaffman MO
    Nurse Pract Forum; 1999 Jun; 10(2):95-105. PubMed ID: 10542586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proprietary hydrocortisone creams. Vasoconstrictor activities and bio-availabilities of six preparations.
    Barry BW; Woodford R
    Br J Dermatol; 1976 Oct; 95(4):423-5. PubMed ID: 974028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of topical corticosteroid activity using the vasoconstriction assay in healthy volunteers.
    Görne RC; Greif C; Metzner U; Wigger-Alberti W; Elsner P
    Skin Pharmacol Physiol; 2007; 20(3):133-40. PubMed ID: 17191036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of topical corticosteroids on human skin.
    Chan HL
    Ann Acad Med Singap; 1991 Jan; 20(1):133-8. PubMed ID: 2029153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topical corticosteroid-induced skin blanching measurement: eye or instrument?
    Haigh JM; Smith EW
    Arch Dermatol; 1991 Jul; 127(7):1065. PubMed ID: 1898473
    [No Abstract]   [Full Text] [Related]  

  • 36. Bioavailability of clobetasol propionate in different vehicles.
    Franz TJ; Lehman PA; Feldman SR; Spellman MC
    Skin Pharmacol Appl Skin Physiol; 2003; 16(4):212-6. PubMed ID: 12784060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Corticosteroid effect and vasoconstriction. 1. Suppression of corticosteroid-induced vasoconstriction in the healthy skin by tolazoline].
    Brehm K; Maucher OM
    Arzneimittelforschung; 1972 Jun; 22(6):1038-9. PubMed ID: 5068352
    [No Abstract]   [Full Text] [Related]  

  • 38. Vasoconstrictor activities and bio-availabilities of seven proprietary corticosteroid creams assessed using a non-occluded multiple dosage regimen; clinical implications.
    Barry BW; Woodford R
    Br J Dermatol; 1977 Nov; 97(5):555-60. PubMed ID: 588468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topical 0.050% betamethasone dipropionate. Pharmacokinetic and pharmacodynamic dose-response studies in humans.
    Pershing LK; Lambert L; Wright ED; Shah VP; Williams RL
    Arch Dermatol; 1994 Jun; 130(6):740-7. PubMed ID: 8002644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vasoconstrictor and systemic activities of topical steroids.
    Child KJ; English AF; Gilbert HG; Hewitt A; Woollett EA
    Arch Dermatol; 1968 Apr; 97(4):407-10. PubMed ID: 4966856
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.